PubMed Journals Articles About "Therapure Biopharma Inc." RSS

12:27 EST 19th November 2018 | BioPortfolio

Therapure Biopharma Inc. PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Therapure Biopharma Inc. articles that have been published worldwide.

More Information about "Therapure Biopharma Inc." on BioPortfolio

We have published hundreds of Therapure Biopharma Inc. news stories on BioPortfolio along with dozens of Therapure Biopharma Inc. Clinical Trials and PubMed Articles about Therapure Biopharma Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Therapure Biopharma Inc. Companies in our database. You can also find out about relevant Therapure Biopharma Inc. Drugs and Medications on this site too.

Showing "Therapure Biopharma" PubMed Articles, all 2

Rethinking the Clinically Based Thresholds of TransCelerate BioPharma for Risk-Based Monitoring.

The quality of data from clinical trials has received a great deal of attention in recent years. Of central importance is the need to protect the well-being of study participants and maintain the integrity of final analysis results. However, traditional approaches to assess data quality have come under increased scrutiny as providing little benefit for the substantial cost. Numerous regulatory guidance documents and industry position papers have described risk-based approaches to identify quality and safety...

Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1.

Neurodegenerative diseases commonly present misfolding and aggregation of one or more proteins, including α-synuclein, β-amyloid and tau. Several research efforts have been made to develop therapeutic agents able to reduce the neurotoxic effects of aggregated proteins. Among these, the inhibition of α-synuclein by small molecules has been considered a promising approach. Areas covered: New bis-heteroaryl derivatives based on the N-[1-(1H-indol-3-yl)hexan-2-yl]-1,3-thiazole-5-carboxamide scaffold with dif...

Quick Search